Form 4: Citius Pharmaceuticals CEO Leonard Mazur Amends Warrant Terms, Maintains Significant Equity Stake
SEC Form 4
CEO Leonard Mazur amended the terms of existing warrants to extend their expiration dates, while maintaining a substantial ownership position in Citius Pharmaceuticals.
Summary
- On August 14, 2024, Leonard L. Mazur, CEO of Citius Pharmaceuticals, amended the terms of warrants to purchase common stock.
- The amendment extended the termination date of warrants originally issued on August 13, 2018, from August 14, 2024, to August 14, 2025; the exercise price is $1.15.
- This involved the cancellation of the old warrant and the grant of a replacement warrant for 3,137,255 shares.
- Similarly, on September 25, 2024, Mazur amended warrants originally issued on September 27, 2019, extending the termination date from September 27, 2024, to September 27, 2025; the exercise price is $0.77.
- This also involved the cancellation of the old warrant and the grant of a replacement warrant for 2,234,700 shares.
- Mazur directly owns 10,255,343 shares of Citius Pharmaceuticals common stock.
- He also holds warrants to purchase 1,165,048 shares at $1.42, exercisable immediately.
- Additionally, Mazur holds multiple stock options with varying exercise prices and expiration dates, totaling 2,565,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it primarily reports changes in warrant terms and equity ownership. There are no explicit positive or negative implications for the company's performance.
Positives
- The extension of warrant expiration dates provides Mazur with more time to potentially exercise these options, aligning his interests with the long-term success of the company.
- Mazur's significant equity stake demonstrates a strong commitment to Citius Pharmaceuticals.
Industry Context
This filing is a routine disclosure related to executive compensation and equity ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The extension of warrant terms could potentially benefit shareholders if Mazur exercises the warrants and contributes to the company's growth.
Key Dates
| Date | Description |
|---|---|
| 08/13/2018 | Original issue date of warrants that were amended on August 14, 2024. |
| 09/27/2019 | Original issue date of warrants that were amended on September 25, 2024. |
| 10/08/2029 | Expiration date of stock options to purchase 175,000 shares at $0.67. |
| 10/06/2030 | Expiration date of stock options to purchase 200,000 shares at $1.01. |
| 07/22/2031 | Expiration date of stock options to purchase 300,000 shares at $2.00. |
| 10/11/2031 | Expiration date of stock options to purchase 650,000 shares at $2.04. |
| 10/04/2032 | Expiration date of stock options to purchase 550,000 shares at $1.25. |
| 10/10/2033 | Expiration date of stock options to purchase 550,000 shares at $0.70. |
| 09/13/2027 | Expiration date of stock options to purchase 40,000 shares at $3.45. |
| 09/04/2028 | Expiration date of stock options to purchase 150,000 shares at $1.62. |
| 08/14/2024 | Date of warrant amendment extending the termination date to August 14, 2025. |
| 08/14/2025 | New expiration date for warrants amended on August 14, 2024. |
| 09/25/2024 | Date of warrant amendment extending the termination date to September 27, 2025. |
| 09/27/2024 | Previous expiration date for warrants amended on September 25, 2024. |
| 09/27/2025 | New expiration date for warrants amended on September 25, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.